The importance of the physician in the generic versus trade-name prescription decision

RAND Journal of Economics

Volumn 29, Issue 1, 1998, Pages 108-136

  Hellerstein, Judith K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; CLINICAL PRACTICE; DECISION MAKING; EPIDEMIOLOGY; HUMAN; PHYSICIAN ATTITUDE; PRESCRIPTION; STATISTICAL MODEL; UNITED STATES;

DECISION MAKING; DRUGS, GENERIC; HEALTH CARE SURVEYS; HUMANS; MODELS, STATISTICAL; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN'S ROLE; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 0032014122     PISSN: 07416261     EISSN: None     Source Type: Journal    
DOI: 10.2307/2555818     Document Type: Article

References (34)

1. ABRAMOWITZ, M. AND STEGUN, I.A. Handbook of Mathematical Functions with Formulas, Graphs, and Mathematical Tables. National Bureau of Standards Applied Mathematics. Washington, D.C.: U.S. Government Printing Office, 1964.
2. ANDERSEN, E.B. Conditional Inference and Models for Measuring. Copenhagen: Mentalhygiejnisk Forsknings Institut, 1973.
3. ARROW, K.J. "Uncertainty and the Welfare Economics of Medical Care." American Economic Review, Vol. 53 (1963), pp. 941-973.
4. ARTHUR, W.B. "Designing Economic Agents That Act Like Human Agents: A Behavioral Approach to Bounded Rationality." American Economic Review, Vol. 81 (1991), pp. 353-359.
5. BAUMGARDNER, J. "Estimation of a Model of Physician-Specific Practice Styles: Applications to Length of Visit and Number of Tests." Mimeo, Department of Economics, Duke University, 1994.
6. THE BOSTON CONSULTING GROUP, INC. "The Changing Environment for U.S. Pharmaceuticals." Mimeo. Boston: The Boston Consulting Group, 1993.
7. BUTLER, J.S. AND MOFFITT, R. "A Computationally Efficient Quadrature Procedure for the One-Factor Multinomial Probit Model." Econometrica, Vol. 50 (1982), pp. 761-764.
8. CAVES, R.E., WHINSTON, M.D., AND HURWITZ, M.A. "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry." Brookings Papers on Economic Activity (1991), pp. 1-48.
9. CHAMBERLAIN, G. "Analysis of Covariance with Qualitative Data." Review of Economic Studies, Vol. 47 (1980), pp. 225-238.
10. _. "Panel Data." In Z. Griliches and M. Intriligator, eds., The Handbook of Econometrics. Amsterdam: North-Holland, 1984.
11. DOERING, P.L., RUSSELL, W.L., MCCORMICK, W.C., AND KLAPP, D.L. "Therapeutic Substitution in the Health Maintenance Organization Outpatient Environment." Drug Intelligence and Clinical Pharmacy, Vol. 22 (1988), pp. 125-130.
12. DRANOVE, D. "Medicaid Drug Formulary Restrictions." Journal of Law and Economics, Vol. 32 (1989), pp. 143-162.
13. DRUG FACTS AND COMPARISONS. St. Louis: J.P. Lippincott Company, 1991.
14. DRUG TOPICS. "Market Research Firm's National Audit Finds Drug Substitution Rate 'Steady' for Last Two Years." June 4, 1991, pp. 12-14.
15. FRANK, R.G. AND SALKEVER, D.S. "Pricing, Patent Loss and the Market for Pharmaceuticals." Southern Economic Journal, Vol. 59 (1992), pp. 165-180.
16. GRABOWSKI H.G. AND VERNON, J.M. "Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Drug Act." Journal of Law and Economics, Vol. 35 (1992), pp. 331-350.
17. HECKMAN, J.J. "The Incidental Parameters Problem and the Problem of Initial Conditions in Estimating a Discrete Time-Discrete Data Stochastic Process." In C.F. Manski and D. McFadden, eds., Structural Analysis of Discrete Data With Econometric Applications. Cambridge, Mass.: MIT Press, 1981a.
18. _. "Statistical Models for Discrete Panel Data." In C.F. Manski and D. McFadden, eds., Structural Analysis of Discrete Data With Econometric Applications. Cambridge, Mass.: MIT Press, 1981b.
19. HELLERSTEIN, J.K. "The Economic Impediments to the Development of New Antibiotics." Contract Paper, U.S. Office of Technology Assessment, 1995.
20. IMS AMERICA, INC. "1995 IMS U.S. Pharmaceutical Market Year-In-Review." Mimeo. Plymouth Meeting, Penn.: IMS America, Inc., 1995.
21. _. "IMS Retail Method-of-Payment Report." Mimeo. Plymouth Meeting, Penn.: IMS America, Inc., 1996.
22. KEANE, M.P. "A Computationally Practical Simulation Estimator for Panel Data." Econometrica, Vol. 62 (1994), pp. 95-116.
23. KENNAN, J. "Simultaneous Equations Bias in Disaggregated Econometric Models." Review of Economic Studies, Vol. 56 (1989), pp. 151-156.
24. KOLASSA, E.M. "Physicians' Perceptions of Prescription Drug Prices: Their Accuracy and Effect on the Prescribing Decision." Journal of Research in Pharmaceutical Economics, Vol. 6 (1995), pp. 23-37.
25. LEIBOWITZ, A., MANNING, W.G., AND NEWHOUSE, J.P. "The Demand for Prescription Drugs as a Function of Cost-Sharing." Social Science and Medicine, Vol. 21 (1985), pp. 1063-1070.
26. LUFT, H.S. Health Maintenance Organizations. New Brunswick, N.J.: Transaction Books, 1987.
27. MASSON, A. AND STEINER, R.L. Generic Substitution and Prescription Drug Prices: Economic Effects of State Drug Product Selection Laws. Staff Report of the Bureau of Economics, U.S. Federal Trade Commission. Washington, D.C.: Federal Trade Commission, 1985.
28. MUNDLAK, Y. "On the Pooling of Time Series and Cross Section Data." Econometrica, Vol. 46 (1978), pp. 69-85.
29. PAULY, M.V. "The Economics of Moral Hazard: Comment." Economic Review, Vol. 58 (1968), pp. 531-537.
30. PHELPS, C.E. "Diffusion of Information in Medical Care." Journal of Economic Perspectives, Vol. 6 (1992), pp. 23-42.
31. PRESS, W.H., FLANNERY, B.P., TUEKOLSKY, S.A., AND VETTERLING, W.T. Numerical Recipes: The Art of Scientific Computing. New York: Cambridge University Press, 1986.
32. SHAH, H.K. "HKS Generic Drug Industry Monitor." Mimeo. Warren, N.J.: HKS & Company, Inc., 1992.
33. TEMIN, P. Taking Your Medicine; Drug Regulation in the United States. Cambridge, Mass.: Harvard University Press, 1980.
34. U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT. Pharmaceutical R&D: Costs, Risks and Rewards. OTA-H-522. Washington, D.C.: OTA, 1993.